{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:17:32Z","timestamp":1787739452153,"version":"build-2784847793"},"reference-count":26,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sci.","Brain Sciences"],"abstract":"<jats:p>Background\/Objectives: The aim of this systematic review is to assess the efficacy, effectiveness, and safety of LAI antipsychotics in patients with schizophrenia and comorbid SUD, providing useful information for clinical decision making and guiding future research in the management of this complex patient population. Methods: The search was conducted on 1 July 2026 and produced 87 results in total; after the screening process, 78 articles were excluded based on the predefined eligibility criteria. The full texts of the remaining 9 studies were retrieved and thoroughly evaluated for inclusion in the qualitative synthesis. Results: The 9 articles that met the criteria for inclusion included 2062 patients in total with follow-up periods varying between 6 months and 3 years. Several studies reported favorable clinical outcomes associated with LAIs; however, not all studies demonstrated clear superiority of LAIs over oral antipsychotics. Conclusions: The present review suggests that LAIs may represent a valuable therapeutic strategy for patients with schizophrenia and comorbid SUD, although the available evidence remains heterogeneous in terms of study design, patient populations, and outcome measures.<\/jats:p>","DOI":"10.3390\/brainsci16090908","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:05:46Z","timestamp":1787735146000},"page":"908","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Acting Injectable Antipsychotics in Schizophrenia and Comorbid Substance Use Disorder: A Systematic Review of the Literature"],"prefix":"10.3390","volume":"16","author":[{"given":"Matteo","family":"Lupi","sequence":"first","affiliation":[{"name":"NHS, Mental Health Department, AST Ascoli Piceno, 63100 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Carano","sequence":"additional","affiliation":[{"name":"NHS, Mental Health Department, AST Ascoli Piceno, 63100 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eros","family":"Rossi","sequence":"additional","affiliation":[{"name":"NHS, Mental Health Department, AST Ascoli Piceno, 63100 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Carlucci","sequence":"additional","affiliation":[{"name":"NHS, Mental Health Department, AST Ascoli Piceno, 63100 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelomarco","family":"Barioglio","sequence":"additional","affiliation":[{"name":"NHS, Mental Health Department, AST Ascoli Piceno, 63100 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Giri","sequence":"additional","affiliation":[{"name":"NHS, Mental Health Department, AST Ascoli Piceno, 63100 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4415-5058","authenticated-orcid":false,"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[{"name":"NHS, Mental Health Department, ASL Teramo, 64100 Abruzzo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Volpe","sequence":"additional","affiliation":[{"name":"Unit of Clinical Psychiatry, Department of Clinical Neurosciences\/DIMSC, School of Medicine, Polytechnic University of Marche, 60121 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7292-2341","authenticated-orcid":false,"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University \u201cG. d\u2019Annunzio\u201d, 66100 Chieti-Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Saha, S., Chant, D., Welham, J., and McGrath, J. (2005). A systematic review of the prevalence of schizophrenia. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020141"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/acps.13291","article-title":"Morbidity and mortality in schizophrenia with comorbid substance use disorders","volume":"144","author":"Batalla","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1176\/appi.ajp.161.3.501","article-title":"Cannabis use and age at onset of schizophrenia","volume":"161","author":"Veen","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/schbul\/sbp016","article-title":"Substance use disorders in schizophrenia-clinical implications","volume":"35","author":"Volkow","year":"2009","journal-title":"Schizophr. Bull."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/pcn.12072","article-title":"Comorbid substance use disorder in schizophrenia: A selective overview of neurobiological and cognitive underpinnings","volume":"67","author":"Thoma","year":"2013","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40263-025-01225-0","article-title":"Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial","volume":"40","author":"Mortazavi","year":"2026","journal-title":"CNS Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chiappini, S., Cavallotto, C., Mosca, A., Di Carlo, F., Piro, T., Giovannetti, G., Pasino, A., Vicinelli, M., Lorenzini, C., and Di Paolo, M. (2024). Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040535"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/1570159X23666241023115252","article-title":"Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review","volume":"23","author":"Santorelli","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.euroneuro.2018.11.1105","article-title":"Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use: A systematic review and meta-analysis","volume":"29","author":"Krause","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41380-024-02694-3","article-title":"All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: A systematic review and meta-analysis","volume":"30","author":"Aymerich","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2174\/15748847113089990056","article-title":"Efficacy and safety of long acting injectable atypical antipsychotics: A review","volume":"8","author":"Marini","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Fu, A.Z., Pesa, J.A., Lakey, S., and Benson, C. (2022). Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia. BMC Psychiatry, 22.","DOI":"10.1186\/s12888-022-03895-2"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41537-017-0025-5","article-title":"Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: Pooled analysis of two double-blind randomized phase three studies","volume":"3","author":"Gopal","year":"2017","journal-title":"Schizophrenia"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Coles, A.S., Knezevic, D., George, T.P., Correll, C.U., Kane, J.M., and Castle, D. (2021). Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.808002"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.4088\/JCP.13m08838","article-title":"Long-acting injectable vs. oral risperidone for schizophrenia and co-occurring alcohol use disorder: A randomized trial","volume":"76","author":"Green","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/070674370605100808","article-title":"Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity","volume":"51","author":"Rubio","year":"2006","journal-title":"Can. J. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2017.05.005","article-title":"Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study","volume":"194","author":"Bermak","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4088\/JCP.12m08331","article-title":"Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder","volume":"74","author":"Sajatovic","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/NMD.0000000000000069","article-title":"Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia","volume":"202","author":"Leatherman","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/eip.13334","article-title":"A naturalistic study on the effectiveness of long-acting antipsychotics in an early intervention program for patients with recent-onset psychosis","volume":"17","year":"2023","journal-title":"Early Interv. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/NDT.S171002","article-title":"Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: Impact on clinical status, substance craving, and quality of life","volume":"14","author":"Cuomo","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/eip.12826","article-title":"Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder","volume":"14","author":"Thibault","year":"2020","journal-title":"Early Interv. Psychiatry"},{"key":"ref_24","first-page":"5","article-title":"Can Substance-Induced Psychoses (SIP) Shed Light on the Paradigm of Schizophrenia?","volume":"2","author":"Mosca","year":"2026","journal-title":"Clin. Neuropsychopharmacol. Addctn."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1038\/s41380-023-02175-z","article-title":"Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders","volume":"28","author":"Boyer","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00406-022-01522-5","article-title":"Effect of long-acting injectable antipsychotics on 1-year hospitalization in bipolar disorder: A mirror-image study","volume":"273","author":"Bartoli","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/9\/908\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:19:00Z","timestamp":1787735940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/9\/908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["brainsci16090908"],"URL":"https:\/\/doi.org\/10.3390\/brainsci16090908","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}